Epidemiologic studies demonstrate that long-term use of NSAIDs is associated with a reduced risk for the development of Alzheimer disease (AD). In this study, 20 commonly used NSAIDs, dapsone, and enantiomers of flurbiprofen were analyzed for their ability to lower the level of the 42-amino-acid form of amyloid β protein (Aβ42) in a human H4 cell line. Thirteen of the NSAIDs and the enantiomers of flurbiprofen were then tested in acute dosing studies in amyloid β protein precursor (APP) transgenic mice, and plasma and brain levels of Aβ and the drug were evaluated. These studies show that (a) eight FDA-approved NSAIDs lower Aβ42 in vivo, (b) the ability of an NSAID to lower Aβ42 levels in cell culture is highly predicative of its in vivo activity, (c) in vivo Aβ42 lowering in mice occurs at drug levels achievable in humans, and (d) there is a significant correlation between Aβ42 lowering and levels of ibuprofen. Importantly, flurbiprofen and its enantiomers selectively lower Aβ42 levels in broken cell γ-secretase assays, indicating that these compounds directly target the γ-secretase complex that generates Aβ from APP. Of the compounds tested, meclofenamic acid, racemic flurbiprofen, and the purified R and S enantiomers of flurbiprofen lowered Aβ42 levels to the greatest extent. Because R-flurbiprofen reduces Aβ42 levels by targeting γ-secretase and has reduced side effects related to inhibition of cyclooxygenase (COX), it is an excellent candidate for clinical testing as an Aβ42 lowering agent.
Jason L. Eriksen, Sarah A. Sagi, Tawnya E. Smith, Sascha Weggen, Pritam Das, D.C. McLendon, Victor V. Ozols, Kevin W. Jessing, Kenton H. Zavitz, Edward H. Koo, Todd E. Golde
Title and authors | Publication | Year |
---|---|---|
A molecular mechanism for ibuprofen-mediated RhoA inhibition in neurons
J Dill, AR Patel, XL Yang, R Bachoo, CM Powell, S Li |
The Journal of neuroscience : the official journal of the Society for Neuroscience | 2010 |
R-flurbiprofen reduces neuropathic pain in rodents by restoring endogenous cannabinoids
P Bishay, H Schmidt, C Marian, A Häussler, N Wijnvoord, S Ziebell, J Metzner, M Koch, T Myrczek, I Bechmann, R Kuner, M Costigan, F Dehghani, G Geisslinger, I Tegeder |
PloS one | 2010 |
Molecular Mechanism for Various Pharmacological Activities of NSAIDS
T Mizushima |
Pharmaceuticals (Basel, Switzerland) | 2010 |
Amyloid precursor protein selective gamma-secretase inhibitors for treatment of Alzheimer's disease
GS Basi, S Hemphill, EF Brigham, A Liao, DL Aubele, J Baker, R Barbour, M Bova, XH Chen, MS Dappen, T Eichenbaum, E Goldbach, J Hawkinson, R Lawler-Herbold, K Hu, T Hui, JJ Jagodzinski, PS Keim, D Kholodenko, LH Latimer, M Lee, J Marugg, MN Mattson, S McCauley, JL Miller, R Motter, L Mutter, ML Neitzel, H Ni, L Nguyen, K Quinn, L Ruslim, CM Semko, P Shapiro, J Smith, F Soriano, B Szoke, K Tanaka, P Tang, JA Tucker, XM Ye, M Yu, J Wu, YZ Xu, AW Garofalo, JM Sauer, AW Konradi, D Ness, G Shopp, MA Pleiss, SB Freedman, D Schenk |
Alzheimer's research & therapy | 2010 |
A potential nitrergic mechanism of action for indomethacin, but not of other COX inhibitors: relevance to indomethacin-sensitive headaches
O Summ, AP Andreou, S Akerman, PJ Goadsby |
The Journal of Headache and Pain | 2010 |
Brain amyloid β protein and memory disruption in Alzheimer's disease
W Xia |
Neuropsychiatric Disease and Treatment | 2010 |
The Nuclear Receptor PPARgamma as a Therapeutic Target for Cerebrovascular and Brain Dysfunction in Alzheimer's Disease
N Nicolakakis, E Hamel |
Frontiers in aging neuroscience | 2010 |
NSAIDs: How they Work and their Prospects as Therapeutics in Alzheimer's Disease
M Sastre, SM Gentleman |
Frontiers in aging neuroscience | 2010 |
Presenilin/gamma-Secretase and Inflammation
CA Saura |
Frontiers in aging neuroscience | 2010 |
Targeting Abeta and tau in Alzheimer's disease, an early interim report
TE Golde, L Petrucelli, J Lewis |
Experimental Neurology | 2010 |
Amyloid-modifying therapies for Alzheimer’s disease: therapeutic progress and its implications
MC Creed, NW Milgram |
AGE | 2010 |
Lost in Translation: Neuropsychiatric Drug Development
RE Becker, NH Greig |
Science Translational Medicine | 2010 |
Drug Development for Alzheimer's Disease: Recent Progress
W Ji, I Ha |
Experimental Neurobiology | 2010 |
Tarenflurbil: mechanisms and myths
M Sano |
Archives of neurology | 2010 |
Diclofenac-induced stimulation of SMCT1 (SLC5A8) in a heterologous expression system: A RPE specific phenomenon
S Ananth, L Zhuang, E Gopal, S Itagaki, B Ellappan, SB Smith, V Ganapathy, P Martin |
Biochemical and Biophysical Research Communications | 2010 |
Effects of nonsteroidal anti-inflammatory drugs on amyloid-β pathology in mouse skeletal muscle
TL Beckett, DM Niedowicz, CM Studzinski, AM Weidner, RL Webb, CJ Holler, RR Ahmed, H LeVine, MP Murphy |
Neurobiology of Disease | 2010 |
R-flurbiprofen improves axonal transport in the Tg2576 mouse model of Alzheimer's Disease as determined by MEMRI
KD Smith, R Paylor, RG Pautler |
Magnetic Resonance in Medicine | 2010 |
Biomarkers in Alzheimer's disease drug development
K Blennow |
Nature Medicine | 2010 |
Bepridil and Amiodarone Simultaneously Target the Alzheimer's Disease - and -Secretase via Distinct Mechanisms
S Mitterreiter, RM Page, F Kamp, J Hopson, E Winkler, HR Ha, R Hamid, J Herms, TU Mayer, DJ Nelson, H Steiner, T Stahl, U Zeitschel, S Rossner, C Haass, SF Lichtenthaler |
The Journal of neuroscience : the official journal of the Society for Neuroscience | 2010 |
β-Amyloid Precursor Protein Mutants Respond to γ-Secretase Modulators
RM Page, A Gutsmiedl, A Fukumori, E Winkler, C Haass, H Steiner |
The Journal of biological chemistry | 2010 |
Neuroinflammatory processes in Alzheimer’s disease
MT Heneka, MK OBanion, D Terwel, MP Kummer |
Journal of Neural Transmission | 2010 |
Mechanisms of action of non-steroidal anti-inflammatory drugs for the prevention of Alzheimer's disease.
Cole GM, Frautschy SA |
CNS & neurological disorders drug targets | 2010 |